On Dec 31, major Wall Street analysts update their ratings for $Axsome Therapeutics (AXSM.US)$, with price targets ranging from $116 to $180.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and maintains the target price at $125.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and maintains the target price at $118.
Wells Fargo analyst Cerena Chen maintains with a buy rating, and maintains the target price at $140.
TD Cowen analyst Joseph Thome maintains with a buy rating, and maintains the target price at $125.
Guggenheim analyst Yatin Suneja maintains with a buy rating, and maintains the target price at $135.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
The overall data from Axsome Therapeutics' ADVANCE-2 and ACCORD-2 trials in Alzheimer's agitation with AXS-05, despite only ACCORD-2 meeting the primary endpoint, is expected to be adequate for approval by 2026. This includes three positive trials and a profile that is both safe and well-tolerated, potentially opening up a $1.1 billion market in the U.S. This optimism is based on anticipated strong physician support for a treatment that doesn't increase mortality risk among the elderly. Despite a decrease in stock price due to the mixed results, the comprehensive data supporting AXS-05 remains robust.
Here are the latest investment ratings and price targets for $Axsome Therapeutics (AXSM.US)$ from 12 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間12月31日，多家華爾街大行更新了$Axsome Therapeutics (AXSM.US)$的評級，目標價介於116美元至180美元。
摩根士丹利分析師Vikram Purohit維持買入評級，維持目標價125美元。
美銀證券分析師Jason Gerberry維持買入評級，維持目標價118美元。
富國集團分析師Cerena Chen維持買入評級，維持目標價140美元。
TD Cowen分析師Joseph Thome維持買入評級，維持目標價125美元。
Guggenheim分析師Yatin Suneja維持買入評級，維持目標價135美元。
此外，綜合報道，$Axsome Therapeutics (AXSM.US)$近期主要分析師觀點如下：
以下爲今日12位分析師對$Axsome Therapeutics (AXSM.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
